Guggenheim Reiterates “Hold” Rating for Teva Pharma (TEVA) Stock; 30 Analysts Bullish Global Payments Inc. (GPN)

January 16, 2018 - By Kurt Siggers

Among 33 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 7 Sell and 17 Hold. Therefore 27% are positive. Teva Pharma has $86 highest and $8 lowest target. $30.24’s average target is 37.96% above currents $21.92 stock price. Teva Pharma had 127 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Neutral” rating by BTIG Research on Wednesday, November 16. The firm earned “Neutral” rating on Wednesday, November 16 by Mizuho. The stock has “Outperform” rating by Oppenheimer on Friday, September 2. Mizuho downgraded Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Monday, October 24 to “Neutral” rating. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Buy” rating by Goldman Sachs on Friday, December 15. Morgan Stanley reinitiated the shares of TEVA in report on Wednesday, July 29 with “Overweight” rating. The stock has “Buy” rating by Bank of America on Tuesday, January 31. JP Morgan downgraded the stock to “Underweight” rating in Monday, November 13 report. Jefferies downgraded it to “Hold” rating and $40 target in Wednesday, November 16 report. As per Friday, July 14, the company rating was maintained by Piper Jaffray.

Among 37 analysts covering Global Payments Inc. (NYSE:GPN), 30 have Buy rating, 1 Sell and 6 Hold. Therefore 81% are positive. Global Payments Inc. had 106 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by Stifel Nicolaus on Thursday, November 9. The rating was maintained by Oppenheimer with “Buy” on Wednesday, August 19. The firm has “Buy” rating by Citigroup given on Tuesday, March 29. Mizuho maintained the stock with “Buy” rating in Friday, October 13 report. The firm earned “Outperform” rating on Thursday, October 6 by Robert W. Baird. The stock of Global Payments Inc. (NYSE:GPN) has “Buy” rating given on Thursday, October 6 by Deutsche Bank. As per Friday, December 11, the company rating was initiated by Credit Suisse. The rating was downgraded by Compass Point on Friday, August 4 to “Hold”. The rating was maintained by Barclays Capital on Monday, October 5 with “Equal-Weight”. Citigroup maintained Global Payments Inc. (NYSE:GPN) rating on Thursday, April 7. Citigroup has “Buy” rating and $78 target. See Global Payments Inc. (NYSE:GPN) latest ratings:

09/01/2018 Broker: Stephens Old Rating: Equal-Weight New Rating: Overweight Upgrade
04/01/2018 Broker: Mizuho Rating: Buy New Target: $115.0 Maintain
21/12/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $122.0 Maintain
27/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $118.0 Maintain
09/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $108.0 Maintain
09/11/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $121.0 Maintain
09/11/2017 Broker: Credit Suisse Rating: Outperform Old Target: $100 New Target: $108 Maintain
09/11/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $103 New Target: $115 Maintain
09/11/2017 Broker: Nomura Rating: Reduce Old Target: $83 New Target: $85 Maintain
09/11/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $106 New Target: $110 Maintain

Global Payments Inc. provides payment solutions for credit cards, debit cards, electronic payments, and check-related services. The company has market cap of $16.69 billion. It operates in three divisions: North America, Europe, and Asia-Pacific. It has a 64.38 P/E ratio. The companyÂ’s services include authorization services, settlement and funding services, customer support and help-desk functions, chargeback resolution, terminal rental, sales and deployment, payment security services, consolidated billing and statements, on-line reporting, industry compliance, and payment card industry security services.

The stock increased 1.57% or $1.62 during the last trading session, reaching $104.88. About 569,156 shares traded. Global Payments Inc. (NYSE:GPN) has risen 21.35% since January 16, 2017 and is uptrending. It has outperformed by 4.65% the S&P500.

Since August 10, 2017, it had 0 insider purchases, and 15 sales for $15.42 million activity. 75,794 shares were sold by MANGUM DAVID E, worth $7.16M on Thursday, August 10. $800,431 worth of stock was sold by BALDWIN ROBERT H B JR on Tuesday, September 12. The insider JACOBS WILLIAM I sold $58,800. The insider SILBERSTEIN ALAN M sold $58,620. $2.47 million worth of Global Payments Inc. (NYSE:GPN) was sold by Sacchi Guido Francesco.

Investors sentiment increased to 1.08 in Q3 2017. Its up 0.19, from 0.89 in 2017Q2. It improved, as 26 investors sold Global Payments Inc. shares while 139 reduced holdings. 59 funds opened positions while 120 raised stakes. 155.40 million shares or 5.29% more from 147.59 million shares in 2017Q2 were reported. Livforsakringsbolaget Skandia Omsesidigt has invested 0.02% in Global Payments Inc. (NYSE:GPN). 2,400 were reported by Quantres Asset Ltd. Swiss Bank stated it has 561,569 shares or 0.06% of all its holdings. Thompson Davis And Inc invested 0.19% in Global Payments Inc. (NYSE:GPN). Jpmorgan Chase Com invested in 3.40 million shares or 0.07% of the stock. M&T National Bank Corporation owns 15,267 shares. Ls Invest Ltd Liability Co holds 0.02% in Global Payments Inc. (NYSE:GPN) or 4,406 shares. Lpl Limited Liability Corporation reported 0.01% stake. Jane Street Gru Lc has invested 0% in Global Payments Inc. (NYSE:GPN). 3,481 were accumulated by Atria Limited Company. Paloma reported 32,372 shares stake. Wisconsin-based Annex Advisory Svcs Ltd Co has invested 0.07% in Global Payments Inc. (NYSE:GPN). Cap Intl Inc Ca invested 0.69% of its portfolio in Global Payments Inc. (NYSE:GPN). American Intl Group accumulated 45,463 shares. Federated Investors Pa, a Pennsylvania-based fund reported 2,625 shares.

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on February, 12. They expect $0.75 EPS, down 44.85% or $0.61 from last year’s $1.36 per share. TEVA’s profit will be $762.18 million for 7.31 P/E if the $0.75 EPS becomes a reality. After $0.95 actual EPS reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -21.05% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.